Literature DB >> 20538423

Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems.

X-F Zhang1, X Qi, B Meng, C Liu, L Yu, B Wang, Y Lv.   

Abstract

AIMS: Alpha-fetoprotein (AFP) loses its potentials in treatment evaluation and prognosis prediction in patients with AFP negative (<or=20 ng/ml) hepatocellular carcinoma (HCC). The present study was to identify the risk factors affecting postoperative survival of AFP negative patients and to determine the optimal staging system in predicting the survival of these patients.
METHODS: The data of 306 in total and 98 AFP negative patients amongst were retrospectively reviewed. The risk factors affecting survivals of the patients were identified. And various staging systems were compared, including the sixth tumor node metastasis (TNM) system, Okuda staging, Cancer of the Liver Italian Program (CLIP) score, the Barcelona Clinic Liver Cancer (BCLC) staging system, and the Japan Integrated Staging (JIS) score.
RESULTS: AFP negative patients tended to have intact tumor capsule and earlier staged tumor by TNM, CLIP and BCLC. The independent risk factors worsening overall survival of AFP negative patients were absence of tumor capsule, Child-Pugh classification B, hepatitis B surface antigen positive and BCLC stage B-C. The risk factors promoting tumor recurrence were tumor size of >3 cm, distribution in two lobes, Okuda stage B-C and BCLC stage B-C.
CONCLUSION: Normal AFP level implies earlier staged tumors. BCLC has the strongest potential in prognosis evaluation in AFP negative patients. Copyright (c) 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538423     DOI: 10.1016/j.ejso.2010.05.022

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  18 in total

1.  Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma.

Authors:  Peng Li; Shan-Shan Wang; Hui Liu; Ning Li; Michael A McNutt; Gang Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

5.  Analysis of DNA methylation in plasma for monitoring hepatocarcinogenesis.

Authors:  Wenqing Huang; Tong Li; Wenli Yang; Xinjuan Chai; Kefei Chen; Ling Wei; Shuwang Duan; Bo Li; Yang Qin
Journal:  Genet Test Mol Biomarkers       Date:  2015-04-29

Review 6.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

7.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

Review 8.  Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.

Authors:  Po-Chih Yang; Cheng-Maw Ho; Rey-Heng Hu; Ming-Chih Ho; Yao-Ming Wu; Po-Huang Lee
Journal:  World J Hepatol       Date:  2016-11-08

9.  Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages.

Authors:  Hui Guo; Tao Wu; Qiang Lu; Miaojing Li; Jing-Yue Guo; Yuan Shen; Zheng Wu; Ke-Jun Nan; Yi Lv; Xu-Feng Zhang
Journal:  Cancer Manag Res       Date:  2018-02-21       Impact factor: 3.989

Review 10.  Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Maria J Citores; Jose L Lucena; Sara de la Fuente; Valentin Cuervas-Mons
Journal:  World J Hepatol       Date:  2019-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.